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Abstract
Among its many roles, the HIV-1 accessory protein Vpu performs a viroporin function and also antagonizes the host cell
restriction factor tetherin through its transmembrane domain. BIT225 is a small molecule inhibitor that specifically targets
the Vpu viroporin function, which, in macrophages, resulted in late stage inhibition of virus release and decreased infectivity
of released virus, a phenotype similar to tetherin-mediated restriction. Here, we investigated whether BIT225 might mediate
its antiviral function, at least in part, via inhibition of Vpu-mediated tetherin antagonism. Using T-cell lines inducible for
tetherin expression, we found that BIT225 does not exert its antiviral function by inhibiting Vpu-mediated tetherin
downmodulation from the cell surface, the main site of action of tetherin activity. In addition, results from a
bioluminescence resonance energy transfer (BRET) assay showed that the Vpu-tetherin interaction was not affected by
BIT225. Our data provide support for the concept that tetherin antagonism and viroporin function are separable on the Vpu
transmembrane and that viroporin function might be cell-type dependent. Further, this work contributes to the
characterization of BIT225 as an inhibitor that specifically targets the viroporin function of Vpu.
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Introduction
The human immunodeficiency virus 1 (HIV-1) has a complex
retroviral genome, which, in addition to encoding the classical
structural and enzymatic proteins Gag, Gag-Pol, Pol and Env, and
the regulatory proteins Tat and Rev, also encodes the four
accessory proteins Vpr, Vif, Vpu and Nef that play multiple roles
in HIV-1 pathogenesis (reviewed in [1,2]). An important function
of the HIV-1 accessory proteins appears to be the antagonism of
host cell restriction factors [3,4,5,6,7,8,9].
The viral protein Vpu is a 16 kDa type I transmembrane
protein, consisting of a N-terminal transmembrane domain (AA 1–
27) and a cytoplasmic domain (AA 28–81) of two consecutive
amphiphatic a-helices (AA 33–49 and AA 57–70) [2,10,11]. At the
cell membrane, Vpu assembles to a multimeric state, most likely as
pentamers, but possibly also as tetramers or hexamers [11,12,13].
The most studied function of Vpu is the downmodulation of CD4,
which permits Env trafficking to the viral assembly site and
subsequent incorporation into the viral membrane. This CD4
downmodulation occurs in the endoplasmic reticulum (ER) and is
mediated by the C-terminal domain of Vpu acting as a transient
adaptor protein to link CD4 to b-transducin repeats-containing
protein (b-TrCP), resulting in proteasomal degradation of CD4
but not of Vpu (reviewed in [14]).
A second function of Vpu is the antagonism of the host cell
restriction factor tetherin (BST-2/CD317/HM1.24). Tetherin
inhibits viral replication late in the viral replication cycle,
inhibiting the budding of nascent virus by directly holding the
budding virus to the cell surface [15,16,17]. Tetherin is
constitutively expressed in various cells, including monocyte-
derived macrophages, activated CD4
+ T-cells and T-cell lines
[18,19,20,21,22,23]. Both this tetherin-mediated restriction as well
as tetherin cell surface expression are interferon responsive, linking
tetherin to the innate immune response [5,15,16,23].
Tetherin is a 30–36 kDa type II transmembrane protein that
consists of a short cytoplasmic N-terminal region (AA 1–21), a
transmembrane region (AA 22–43), an ectodomain (AA 44–160),
and a C-terminal glycosylphosphatidylinostol (GPI) anchor
[19,24]. Tetherin localizes to the plasma membrane, the trans-
Golgi network (TGN) and the early and recycling endosomes, and
cycles between these membrane compartments [24,25]. Tetherin-
mediated restrictive activity has commonly been attributed to its
cell surface expression, though additional surface-independent
mechanisms have been suggested but not yet characterized
[5,15,21,23,26,27].
In HIV-1 infection, the viral protein Vpu antagonizes tetherin-
mediated restriction and promotes down-modulation of tetherin
from the cell surface where viruses assemble and bud [28,29].
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degradation by the proteasome and/or the lysosome, and the
sequestration of tetherin in intracellular compartments. For the
degradation of tetherin, Vpu employs b-TrCP that acts in a
fashion similar to that which occurs during degradation of CD4.
Vpu recognizes tetherin through an interaction between the
transmembrane domains of these two proteins. Molecular
mapping revealed a few amino acids on each transmembrane
domain that are crucial for functional interactions (Vpu: A14, A18
and W22) [30,31,32,33,34,35,36]. In Vpu transmembrane multi-
mers, these residues are predicted to be outside-facing [33];
modeling of the tetherin transmembrane domain indicates a sided
positioning of crucial amino acid residues in the helix and supports
the existence of a direct Vpu-tetherin interface [5].
In addition to tetherin antagonism and virus release, the
transmembrane domain of Vpu also functions as a cation-selective
ion channel (also called viroporin) in a multimeric state
[11,37,38,39,40]. Interestingly, the A18H mutation of an
outside-facing residue important for Vpu-tetherin interaction
rendered the viroporin activity of Vpu sensitive to rimantadine,
an inhibitor of the viroporin function of influenza A M2 protein
[41]; this suggests a possible link between Vpu viroporin function
and Vpu-mediated promotion of virus release by tetherin
antagonism. However, a recent study reported that tetherin
antagonism and viroporin function are separable functions of Vpu.
Mutation of the Vpu amino acids A14 and A18 to asparagines
abrogated tetherin antagonism without affecting viroporin func-
tion [42]. Also, an S23A mutation eliminated viroporin function
but did not affect anti-tetherin activity [42,43].
BIT225 (N-[5-(1-methyl-1H-pyrazol-4-yl)-napthalene-2-carbon-
yl]-guanidine: CASNo. 917909-71-8) is a novel small molecule
inhibitor of HIV-1 Vpuviroporin function. In addition to itsactivity
against Vpu, BIT225 also abrogates the viroporin function of
hepatitis C virus (HCV) protein p7 [44,45]. Further, BIT225
displays a synergistic effect in HCV infections with interferon a2b
(IFNa2b) in vitro [44], which also stimulates tetherin expression as
part of the interferon-induced antiviral state [23,32]. In monocyte-
derived macrophages (MDMs), which express high levels of
endogenous tetherin and which represent a long-lived virus
producing reservoir in HIV-1 infection, BIT225 efficiently blocks
HIV-1 virus release and reduces the infectivity of released virus
[45,46]. Tetherin also inhibits the release of Dvpu virus and renders
released virus less infectious [15,16,32]. Interestingly, BIT225exerts
higher antiviral efficacy in MDMs than in CD4
+ T-cells, even
though the latter express lower endogenous tetherin levels [45].
Therefore, we have now investigated whether the antiviral
activity of BIT225 might be partly related to inhibition of Vpu-
mediated tetherin-antagonism in tetherin expressing CD4
+ T-cell
lines. However, we were not able to detect a tetherin-mediated
impact on BIT225 function, which suggests that BIT225
specifically blocks Vpu viroporin function. These data also support
the concept that viroporin function and virus release are separable
functions of the Vpu transmembrane domain [42], and that the
viroporin function of Vpu may be cell type specific [45].
Results
First we assessed the cyototoxicity of BIT225 on the following
T-cell lines: SupT1-tetherin
pos (transduced with human tetherin),
SupT1-tetherin
neg (transduced with an empty vector), SupT1-
tetherin
hTMa1 (transduced with a chimeric tetherin resistant to
Vpu mediated antagonism), and CEM-SS cells [23,32,47]. CEM-
SS cells express detectable endogenous levels of cell surface
tetherin, and this correlates with their lower permissiveness to Dvpu
viral replication compared to wt viral replication [23]. Cells were
cultured in media containing BIT225 at concentrations of 0.04,
0.2, 1, 5, 10, 25 or 50 mM for 72 h, after which we assessed cell
viability using flow cytometry detection of side scatter (SSC) and
forward scatter (FSC), comparing BIT225 treated populations to
dimethyl sulfoxide (DMSO) treated controls (Figure S1). Non-
linear regression analysis revealed that BIT225 had a 50%
cytotoxic concentration of 32–50 mM in the transduced Sup-T1
cell lines (Fig. 1A–C, Table 1). CEM-SS cells showed reduced
sensitivity to BIT225 (extrapolated 50% cytotoxic concentration:
67 mM) (Fig. 1D; Table 1).
We then assessed the inhibitory effect of BIT225 on virus release
in these cell lines infected with equal amounts of wt or Dvpu virus
and cultured in media containing BIT225 at concentrations of
0.04, 0.2, 1, 5, 10, 25 or 50 mM at 72 h post infection (p.i.) (Fig. 1,
Table 1). The half maximal inhibitory concentrations (IC50) for
virus release in wt infected populations were ,18 mM in SupT1-
tetherin
neg cells, ,11 mM in tetherin expressing SupT1-tetherin
pos
cells and ,50 mM in the SupT1-tetherin
hTMa1 control cell line,
expressing chimeric tetherin, resistant to Vpu antagonism.
Regarding Dvpu infected populations, the extrapolated IC50
concentrations were ,54 mM (SupT1-tetherin
neg), ,90 mM
(SupT1-tetherin
pos) and ,86 mM (SupT1-tetherin
hTMa1), respec-
tively (Fig. 1A–C; Table 1). To assess the impact of BIT225 on
Vpu-mediated virus release (‘Vpu effect’), we normalized virus
release in wt infected populations to that of Dvpu infected
populations (Fig. 1E). In SupT1-tetherin
neg cells, the ‘Vpu effect’
remained stable at 2.4–3 at BIT225 concentrations up to 10 mM,
after which it declined to ,1.2, which indicates almost equal virus
release in wt and Dvpu infected populations. A similar trend was
observed in the Vpu-resistant SupT1-tetherin
hTMa1 cells, express-
ing tetherin, though the reduction only occurred at 25 mM (fold
change: ,1.6). In CEM-SS cells, virus release in wt and Dvpu
infected populations was not significantly affected by BIT225
concentrations of up to 50 mM, and the ‘Vpu effect’ remained
relatively stable at ,3–3.5 fold (Fig. 1D; Table 1).
In SupT1-tetherin
pos cells, however, the Vpu effect was
generally stronger at concentrations up to 5 mM (0.04 mM: 9.2,
5 mM: 8.5), with a peak at 0.2 mM BIT225 (ratio: 12). Starting at
10 mM the ratio decreased (10 mM: 6.5, 25 mM: 5, 50 mM 1.6) to
levels similar to those obtained with the other cell lines (Fig. 1E).
The apparently elevated sensitivity of SupT1-tetherin
pos cells to
BIT225 might be due to an inhibition of Vpu-mediated tetherin
antagonism. Therefore, we assessed whether BIT225 might
influence tetherin cell surface expression levels in uninfected cells
and/or might affect tetherin modulation following infection. Cells
were infected with wt or Dvpu virus and cultured in the absence
(DMSO control) or presence of 10 mM BIT225, a concentration
almost equal to the IC50 in SupT1-tetherin
pos cells for virus
release. At 72 h p.i., tetherin cell surface expression in infected and
uninfected cells was assessed using flow cytometry; infected and
uninfected cells were distinguished based on virus-derived
enhanced green fluorescent protein (eGFP) expression (Figure
S2). We were able to specifically detect and quantify tetherin cell
surface expression and its modulation following infection in
SupT1-tetherin
pos cells, SupT1-tetherin
hTMa1 cells, and CEM-SS
cells (Fig. 2, Figure S2); cell surface tetherin expression in SupT1-
tetherin
neg cells was at the limit of specificity of detection (Fig. 2A).
In wt infected SupT1-tetherin
pos cells, tetherin surface expression
was downregulated by ,70% compared to uninfected controls. In
Dvpu infected cells, detection of cell surface tetherin was increased
(,50%), as previously reported [47]. Treatment with 10 mM
BIT225 did not affect tetherin cell surface levels in uninfected cells,
neither did BIT225 affect either Vpu-mediated tetherin down-
Vpu Inhibitor BIT225 and Vpu-Tetherin
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toxicity. The T-cell lines SupT1-tetherin
pos (A), SupT1-tetherin
hTMa1 (B), SupT1-tetherin
neg (C) and CEM-SS cells (D) were infected with equal amounts
of wt or Dvpu virus by spinoculation and cultured in media containing BIT225 at concentrations of 0.04, 0.2, 1, 5, 10, 25 and 50 mM. Virus release was
assessed at 72 h p.i. by reverse transcriptase assay (solid lines). Cell viability was assessed by flow cytometry using side scatter and forward scatter in
the presence of BIT225 (0.04, 0.2, 1, 5, 10, 25 and 50 mM) compared to DMSO controls (dotted lines) (A-D). Normalized data from three independent
experiments, analyzed for non-linear regression, are presented; error bars represent standard error of the mean (SEM). (E) The relative Vpu-mediated
impact of virus release from A-D was determined by normalizing virus release in wt infected populations relative to virus release in Dvpu infected
populations.
doi:10.1371/journal.pone.0027660.g001
Table 1. IC50 concentrations and 50% viability concentrations of BIT225 determined by non-linear regression analysis.
T-cell line 50% cell viability (BIT225 [mM]) IC50 – wt (BIT225 [mM]) IC50 - Dvpu (BIT225 [mM])
SupT1-tetherin
neg 49.48 18.44 54.19
SupT1-tetherin
pos 32.25 11.15 89.97
SupT1-tetherin
hTMa1 43.67 49.59 85.51
CEM-SS 67.21 ..100 ..100
doi:10.1371/journal.pone.0027660.t001
Vpu Inhibitor BIT225 and Vpu-Tetherin
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SupT1-tethern
pos cells. In SupT1-tetherin
hTMa1 cells, tetherin
levels were not downregulated following wt infection compared to
uninfected cells, but slightly upregulated (,35%); infection with
Dvpu virus resulted in an upregulation of cell surface tetherin by
,120%. Cell surface tetherin levels followed the same trend in
BIT225 treated cells, but were generally increased, compared to
the respective untreated populations (uninfected: 65% increase; wt
infections: 60% increase; Dvpu infections: 35% increase). In CEM-
SS cells, wt infection decreased cell surface tetherin by ,75%,
while Dvpu infected cells showed a decrease of ,20% in cell
surface tetherin expression, compared to uninfected populations,
as previously described [23]. BIT225 did not affect tetherin cell
surface levels in uninfected CEM-SS cells or tetherin modulation
in infected cells.
To further test whether BIT225 might affect Vpu-tetherin
interactions, we performed a bioluminescence resonance energy
transfer assay (BRET). In this assay, energy transfer is observed
only upon close proximity (,10 A ˚)o fRenilla luciferase (RLuc)-
fused tetherin and enhanced yellow fluorescent protein (eYFP)-
fused Vpu, indicating a direct interaction. A disruption of
interaction results in a decreased eYFP emission signal following
luciferase excitation. The assay was performed in the absence
(DMSO control) or in the presence of 10 mM BIT225, which is
close to the IC50 in regard to virus release in tetherin expressing
SupT1-tetherin
pos cells. We were able to specifically detect
bioluminescence energy transfer in our system. The negative
control, wherein an eYFP protein is used in the absence of Vpu,
resulted in a background signal of ,25; the positive control,
provided by a RLuc-eYFP fusion protein, exhibited a relative
signal of ,49. The use of RLuc-fused tetherin and eYFP-fused
Vpu resulted in a signal of ,52 in the absence of BIT225 and a
signal of ,51 in the presence of BIT225 (Fig. 3). Although these
ratios were not significantly different from each other nor different
from the positive control, the difference from the negative control
was significant. Thus, while the BRET assay indicates a specific
Vpu-tetherin interaction, BIT225 does not appear to influence
Vpu-tetherin interactions in this system, confirming the absence of
Vpu-tetherin modulation by BIT225 in regard to virus release and
tetherin cell surface expression.
Figure 2. BIT225 does not modulate tetherin cell surface expression. (A) Representative overlay of tetherin cell surface expression levels. Cell
surface tetherin levels assessed by flow cytometry detection of PerCP-levels in SupT1-tetherin
pos cells (orange), SupT1-tetherin
hTMa1 cells (turquoise),
SupT1-tetherin
neg (green) and CEM-SS cells (rose). Controls are unstained SupT1-tetherin
pos cells (red) and SupT1-tetherin
pos cells stained with
secondary antibody only (blue). (B–D) Geometric means of cell surface expression of tetherin in SupT1-tetherin
pos cells (B), SupT1-tetherin
hTMa1 cells
(C) and CEM-SS cells (D) in the presence of BIT225 [10 mM] or absence of BIT225 (DMSO control). Cells were infected with equal amounts of wt and
Dvpu BR-NL43-IRES-eGFP. At 48 h p.i., cells were gated into uninfected and infected populations, based on their virus-derived eGFP expression profile,
and cell surface levels of tetherin were assessed. Data are derived from a minimum of three independent experiments.
doi:10.1371/journal.pone.0027660.g002
Vpu Inhibitor BIT225 and Vpu-Tetherin
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BIT225 is a novel antiviral compound that inhibits the
viroporin function of HIV-1 Vpu and HCV p7 [44,45]. In
HIV-1 infections, MDMs represent an important active viral
reservoir [48]. Treatment of MDMs with BIT225, and subsequent
inhibition of Vpu (viroporin function), inhibits viral replication at a
late stage and reduces virus release and viral infectivity [45,46].
HIV-1 infection of T-cells proved to be less sensitive to BIT225-
mediated inhibition of Vpu [45]. In HCV infections, BIT225 is
synergistic with IFNa2b in vitro, which also induces tetherin
expression across a wide range of cells including CD4
+ T-cells, the
primary target for HIV-1 [16,21,23,32,44]. Several CD4
+ T-cell
lines, including CEM-SS, display detectable levels of endogenous
tetherin at the cell surface, which correlates with their reduced
permissiveness towards Dvpu replication [23]. Tetherin is a host
cell restriction factor that acts late in the viral life cycle, inhibiting
release of nascent virus by directly linking the viral and cellular
membranes [15,16,26]. In HIV-1 infection, Vpu antagonizes
tetherin-mediated restriction by downmodulating tetherin from
the cell surface [15,26]; compared to CD4
+ T-cells, MDMs
express higher endogenous tetherin levels than CD4
+ T-cells
[21,23]. Tetherin also reduces the infectivity of released virus and
there is evidence that tetherin also inhibits direct cell-to-cell spread
of HIV-1 [47,49], though the extent of this latter effect is still
debated [50].
Vpu mediates its viroporin function and its tetherin antagoniz-
ing activity via its transmembrane domain. Although the Vpu
transmembrane domain is responsible for both the viroporin
function and tetherin antagonism, a recent report suggests that
these two activities can be distinguished [42]. Here, we
investigated whether the Vpu-specific inhibitor BIT225 might
partially act via inhibition of Vpu-mediated tetherin antagonism, in
addition to its known inhibitory effect on Vpu viroporin function
[38,45,46]. To this end, we used a panel of SupT1 T-cell lines
which are inducible for expression of human tetherin (SupT1-
tetherin
pos) or a Vpu-resistant tetherin variant, resistant due to a
chimeric transmembrane domain (SupT1-tetherin
hTMa1); the
control cell line was transduced with an empty vector and tetherin
levels in that cell line were below the sensitivity level of tetherin
detection by flow cytometry [32,47]. In this panel, tetherin
expression is independent of the multifaceted IFN response.
Therefore, this system allows the specific investigation of tetherin-
mediated effects and Vpu-mediated countermeasures. In addition,
a CEM-SS cell line, which expresses intermediate levels of tetherin
was used [23]. The effects of BIT225 on cell viability, virus release,
Vpu-tetherin interaction and Vpu-mediated downmodulation
from the cell surface were investigated.
BIT225 exerts similar effects on the viability of SupT1-
tetherin
neg cells and SupT1-tetherin
hTMa1 cells, while the tetherin
expressing SupT1tetherin
pos cell line was more sensitive to
BIT225, exhibiting reduced viability at lower concentrations. As
the only difference between these cell lines is the expression of
tetherin, the reduced cell viability of these SupT1-tetherin
pos cells
in response to BIT225 may be due to higher tetherin expression in
these cells, leading to their increased fragility when cultured with
drug (Fig. 2A). Also, all SupT1 cell lines showed decreased viability
in the presence of BIT225 when compared to CEM-SS cells (Fig. 1;
Table 1). Transduced SupT1-based cell lines need to be cultured
in the presence of puromycin, G418 and doxycycline to maintain
the inserted tetherin gene and to induce tetherin expression. It is
not known whether these compounds might sensitize cells to
BIT225 or whether drug interactions might occur in this
circumstance.
In the SupT1 cell lines examined, BIT225 inhibited virus
release in a Vpu-specific manner; BIT225 IC50 concentrations
were lower in the presence of Vpu, comparing wt to Dvpu
infections (Fig. 1; Table 1). Since the IC50 values were less than 3-
fold lower than the extrapolated 50% cytotoxic concentrations of
BIT225 in the Sup-T1 cell lines, and to achieve a more meaningful
readout, we also calculated the relative impact of Vpu (‘Vpu
effect’) by normalizing virus release in wt-infected compared to
Dvpu-infected populations over a range of BIT225 concentrations.
At low concentrations of BIT225, Vpu promoted virus release in
all SupT1 cell lines, an effect that was antagonized by increasing
the concentration of BIT225 (Fig. 1E). As the SupT1-tetherin
neg
cell line does not exhibit detectable levels of tetherin expression
(Fig. 2A), the Vpu-mediated impact is due to the viroporin
function of Vpu. Therefore, it is reasonable to argue that the
decreased impact of Vpu on virus release in the presence of
increasing levels of BIT225 is due to BIT225-mediated inhibition
of Vpu viroporin function. The same argument applies to the
SupT1-tetherin
hTMa1 cell line, transduced with a tetherin variant
that is resistant to Vpu-mediated antagonism.
In this assay system and without the addition of drug, the
increased Vpu effect on virus release in SupT1-tetherin
pos cells
compared to the other cell lines, is due to the Vpu-mediated
tetherin antagonism, which promotes virus release [15,16,23,32].
The Vpu effect appeared to be more sensitive to BIT225 in
SupT1-tetherin
pos cells compared to the other SupT1 cell lines.
However, the similarity of the BIT225 therapeutic ratios (50%
viability concentration/IC50 concentration) in wt infection of
SupT1-tetherin
pos (2.89) and SupT1-tetherin
neg (2.68) cells does
not support such an interpretation.
In the CD4
+ T-cell line CEM-SS, Vpu antagonized tetherin-
meditated restriction of virus release and downmodulated tetherin
from the cell surface (Fig. 1E & Fig. 2A&D [23]). Interestingly,
Figure 3. BIT225 does not affect Vpu-tetherin interactions. A
bioluminescence resonance energy transfer (BRET) assay was used to
study Vpu-tetherin interaction. Tetherin fused to RLuc (Renilla
luciferase) and Vpu fused to eYFP (enhanced yellow fluorescent
protein) were transfected into 293T cells. At 48 h post transfection,
eYFP emission was detected following RLuc excitation, representing
energy transfer between these two proteins at close proximity (,10 A ˚).
BRET assays were performed in the presence of BIT225 [10 mM] or its
absence (DMSO control). The negative control represents cotransfection
of an empty (Vpu-negative) eYFP vector and the tetherin-RLuc vector;
the positive control is a vector coding for eYFP-RLuc-fusion protein.
Data are derived from a minimum of three independent experiments,
performed in duplicate; error bars represent SEM.
doi:10.1371/journal.pone.0027660.g003
Vpu Inhibitor BIT225 and Vpu-Tetherin
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in contrast to the panel of Sup-T1 cell lines, the ‘Vpu effect’ in
CEM-SS remained stable over the range of BIT225 concentra-
tions used (Fig. 1E & Fig. 2A&D). Taken together, this suggests a
reduced need for Vpu viroporin function in CEM-SS cells for viral
replication, and might also reflect a potential alteration of a
cellular function in this immortalized cell line, rendering it less
sensitive to BIT225 toxicity. The dependence of virus release on
Vpu-mediated tetherin antagonism, paired with apparent insen-
sitivity towards inhibition of Vpu-viroporin function in CEM-SS
cells, further supports the concept of tetherin antagonism and
viroporin activity as being separable functions of Vpu.
Investigation of the Vpu-tetherin interrelationship by detection
of Vpu-mediated tetherin cell surface downregulation was
performed by flow cytometry (Fig. 2). Vpu-tetherin interactions
were also studied using a BRET assay (Fig. 3). Both methods
confirmed the absence of additional effects of BIT225 on Vpu-
tetherin interactions. We have been able to induce tetherin
expression in SupT1-tetherin
pos cells and SupT1-tetherin
hTMa1
and to specifically detect cell surface tetherin expression using flow
cytometry (Fig. 2A). In SupT1-tetherin
pos cells, wt infection led to
tetherin cell surface downregulation, while cell surface tetherin was
upregulated in cell populations following Dvpu infection compared
to uninfected cells, as previously described [47,51]. The presence
of BIT225 at levels of 10 mM neither affected cell surface tetherin
expression in uninfected cells nor Vpu-mediated tetherin down-
modulation or upregulation following Dvpu infections (Fig. 2B).
This shows that the sensitivity of wt infection (and the normalized
‘Vpu effect’) in regard to the tetherin expressing SupT1-tetherin
pos
cell line is independent of interference with the Vpu function in
tetherin antagonism. Interestingly, BIT225 mediated an increase
in tetherin cell surface detection in SupT1-tetherin
hTMa1 cells
(Fig. 2C). This was true in both uninfected cells and cells infected
with wt or Dvpu virus, although the effect was less pronounced in
the Dvpu infected population. HIV-1 Vpu was not able to
antagonize and downmodulate the hTMa1-tetherin variant from
the surface of wt infected cells; rather cell surface levels increased,
although to lower levels than in the Dvpu infected cells. The
resistance to Vpu-mediated downregulation is in agreement with
Vpu-resistance and virus release (Fig. 1; [32]). This different
tetherin expression profile in CEM-SS cells (Vpu-independent
tetherin downmodulation) has been previously described and
supports the existence of additional anti-tetherin mechanisms
following infection, which appear to not be affected by BIT225
(Fig. 2D [21,23]).
To examine the possible effect of BIT225 on Vpu-tetherin
interactions, we employed a Vpu-tetherin BRET assay that
specifically detects bioluminescence resonance energy transfer
between Vpu and tetherin when both are in immediate proximity
(,10 A ˚), indicative of direct interaction. Our findings support
the concept that Vpu and tetherin interact directly (Fig. 3)
[15,16,26,30,31,32,33]. However, BIT225 did not modulate the
BRET signal, indicating that BIT225 does not interfere with Vpu-
tetherin interaction (Fig. 3). As Vpu in regard to tetherin
antagonism might be outside-facing in Vpu multimers whereas
viroporin function is believed to be focused at the inner face of
Vpu multimers, the absence of BIT225-mediated Vpu-tetherin
interactions gives support to the idea that BIT225 specifically
targets the viroporin function, most likely on the inside of Vpu
multimers.
Furthermore, these results indicate that viroporin function and
tetherin antagonism represent distinct functions of the Vpu
transmembrane domain in agreement with a recent report that
studied this topic using a mutagenesis approach [42]. These
findings are also in agreement with the modeling of a putative
Vpu-tetherin interaction surface, based on nuclear magnetic
resonance (NMR) structures, and the discovery that amino acid
residues necessary for tetherin antagonism are outside-facing on
the Vpu multimer [5,33], while residues crucial for viroporin
function are predicted to face the inside of the Vpu multimer
[42,43]. However, both functions affect virus release and viral
infectivity at a late stage in the viral replication cycle [32,45].
Our data further support the characterization of BIT225 as a
specific inhibitor of the viroporin function of Vpu and a potentially
useful agent to target cellular viral reservoirs. Our results also
imply that Vpu viroporin function may be cell type specific, as the
efficacy of BIT225 has been reported to be greater in MDMs than
in T-cells. However, specific work with MDMs may be difficult to
achieve, due to a lack of functional MDM cell lines and a scarcity
of knowledge on the role of tetherin in MDMs.
Materials and Methods
Cells
CEM-SS cells were obtained from the NIH AIDS Research and
Reference Reagent Program [52] and were maintained in RPMI-
1640 culture medium (Gibco) supplemented with 10% bovine
serum albumin (BSA). Sup-T1 cells were also obtained from the
NIH AIDS Research and Reference Reagent Program [52].
Transduced Sup-T1 cells were maintained in RPMI-1640
supplemented with 10% tetracycline-free BSA, 2 mg/ml puromy-
cin (Sigma), and 1 mg/ml G418 (Sigma). Expression of human
tetherin or its variant hTMa1 in Sup-T1 cells, was induced using
100 ng/ml doxycycline (Sigma) [32,47,51]; Sup-T1 cells stably
transduced with the wt human tetherin gene (SupT1-tetherin
pos),
an empty vector (SupT1-tetherin
neg), or the Vpu-resistant variant
(SupT1-tetherin
hTMa1), wherein the first nine amino acids of the
transmembrane domain are replaced by the respective residues of
tetherin from African green monkeys, were previously described
[32].
Viruses
Site-directed mutagenesis, using the QuickChange II XL Site-
Directed Mutagenesis Kit (Stratagene), was used to introduce
nucleotide changes into the coding regions of vpu, resulting in two
stop codons at the beginning of Vpu coding regions of the viral
clone pBR43-IRES-eGFP (NIH AIDS Research and Reference
Reagent Program), expressing enhanced green fluorescent protein
(eGFP) from an internal ribosomal entry site downstream of nef
[53]. Virus was produced in 293T cells using Lipofectamine2000
(Invitrogen) as a transfection reagent. Virus was collected after
48 h, filtered (0.45 mm), and viral capsid/p24 protein (CA p24)
content was quantified by a Vironostika HIV-1 Ag kit (bioMe ´r-
ieux).
Compound
BIT225 (Batch 106R) was provided by Biotron Limited. The
compound was dissolved in anhydrous dimethyl sulfoxide (DMSO)
at 100 mM and was further diluted in culture media to working
concentrations of 0.04, 0.2, 1, 5, 10, 25 or 50 mM.
HIV-1 infections
Cell populations were infected with equal amounts of wt or Dvpu
virus to ,10% infection rates, as determined by flow cytometric
detection of virus-derived eGFP expression at 72 h p.i., in order to
minimize superinfection events. Sup-T1 cells were infected with
600 ng CA p24 per 10
6 cells (CEM-SS: 300 ng CA p24 per 10
6
cells) by spinoculation (1,500 x g, at 37uC for 2 h), followed by
Vpu Inhibitor BIT225 and Vpu-Tetherin
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centrifugation and cell washing. Cells (10
5 cells/ml) were then
cultured in media containing BIT225 at concentrations of 0.04,
0.2, 1, 5, 10, 25 or 50 mM. At 72 h p.i., virus release and tetherin
cell surface expression were assessed.
Virus release
Virusreleaseintothesupernatantwasanalyzedat72 hp.i.usinga
quantitative reverse transcription-based assay [54]. Virus release was
determined from populations infected with wt or Dvpu virus, cultured
in media containing BIT225 at concentrations of 0.04, 0.2, 1, 5, 10,
25 or 50 mM, or equivalent amounts of DMSO solvent only.
Cell viability
Cellviability was determined through flow cytometrydetection of
forward scatter (FSC) and side scatter (SSC) of cells cultured in
BIT225-containg media (0.04, 0.2, 1, 5, 10, 25 or 50 mM) or media
with DMSO as a control for 72 h. Flow cytometry analysis was
performed on a minimum of 30,000 cells using a LSR II instrument
(Becton Dickinson) and FlowJo 7.5 software (Tree Star).
Cell surface tetherin
Levels of cell surface tetherin expression in uninfected popula-
tions or populations infected with wt or Dvpu virus were assessed by
flow cytometry for peridinin chlorophyll protein (PerCP) at 72 h
p.i.; populations were cultured either in the presence of 10 mM
BIT225 or DMSO (0.1 ml/ml). Staining for cell surface tetherin was
performed using a primary rabbit anti-human-tetherin polyclonal
antibody (1:3000) (NIH AIDS Research and Reference Reagent
Program [21]), followed by a PerCP-labeled secondary goat anti-
rabbit antibody (1:250) (Santa Cruz Biotechnology). Cells were
stained at 4uC for 30 min and fixed in 4% paraformaldehyde for
25 min. Uninfected and infected cells were distinguished by virus-
derived eGFP expression. Flow cytometry analysis was performed
on a minimum of 30,000 cells using a LSR II instrument (Becton
Dickinson) and FlowJo 7.5 software (Tree Star).
Vpu-tetherin bioluminescence resonance energy transfer
assay (BRET)
Human tetherin was cloned into the pRLuc-C3 vector (BioSignal
Packard). Vpu was cloned into the pEYFP-N1 vector (Clontech).
The constructs were transfected into HEK293T cells using
Lipofectamine2000 (Invitrogen) as a transfection reagent. After
6 h, transfection media were replaced by media containing either
10 mM BIT225 or DMSO (to equivalent amounts). Cells were
collected 48 h post-transfection and washed twice in PBS. Transfer
of bioluminescence was assessed using a Synergy
TM 4 Multi-Mode
Microplate Reader (Bioteck). To measure fluorescence of RLuc,
coelenterazine H (Promega) was added to a final concentration of
5 mM in PBS. For measurement of EYFP only, cells were
resuspended in PBS. The negative control used was an empty
EYFP-N1 vector cotransfected with Rluc-tetherin and the positive
control was a vector with EYFP fused to RLuc (EYFP-RLuc). A
minimum of 10
5 cells were analyzed from each experiment.
Statistical analysis
Data from at least three independent experiments were analyzed
utilizing GraphPad PRISM 5 software. Differences were analyzed
for statistical significance using a one-way analysis of variance
(ANOVA) with Bonferroni’s post-test for groups and Student’s t-test
for pairs of data. GraphPad PRISM 5 software was also utilized to
determine IC50 values in a non-linear regression analysis.
Supporting Information
Figure S1 Cell viability assessment. SupT1-tetherin
pos,
SupT1-tetherin
hTMa1, SupT1-tetherin
neg and CEM-SS cells were
cultured in media containing BIT225 at concentrations of 0.04,
0.2, 1, 5, 10, 25 and 50 mM or DMSO. At 72 h p.i., cell viability
was assessed, based on flow cytometry detection of forward scatter
(FSC) and side scatter (SSC). Representative dot plots are shown.
(PDF)
Figure S2 Gating strategy and readout for cell surface
tetherin expression. Representative gating for infected and
uninfected cell populations and representative readout of cell
surface tetherin modulation following infection are shown. SupT1-
tetherin
pos cells, SupT1-tetherin
hTMa1 cells, SupT1-tetherin
neg and
CEM-SS cells were infected with equal amounts of wt BR-NL43-
IRES-eGFP. At 48 h p.i., live cells were detected according to
their flow cytometric FSC/SSC profiles. Live cells were gated into
uninfected and infected populations, based on their virus-derived
eGFP expression profile. Tetherin cell surface expression was
determined in uninfected populations (red) and infected popula-
tions (blue) via detection of PerCP and presented as overlays.
Geometric means of PerCP signal in uninfected and infected
populations were assessed for relative quantification and compar-
ison of cell surface expression levels of tetherin.
(PDF)
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